Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 3-session online tool aims to calm caregivers' fear as cancer advances

NCT ID NCT07752992

Symptom relief Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests a short, three-session online program designed to help caregivers of people with advanced prostate cancer manage their fear that the cancer will progress. The program teaches techniques like detached mindfulness to help caregivers relate to worrying thoughts in a new way. Researchers are checking whether the program is practical and acceptable to caregivers, and whether it may reduce their fear and anxiety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Conquer Fear Carer Brief, a three-session online psychological intervention using detached mindfulness and attention training techniques
What this could lead to
If successful, this brief online program could offer a practical way to help caregivers manage the intense fear that a loved one's cancer may progress, improving their emotional well-being.
What could go wrong
This is a small feasibility study with only 14 participants, so results may not apply broadly. The intervention is brief and may not be enough for everyone, and some participants might not find it helpful or could experience temporary discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Self-identified caregiver of a patient with metastatic, non-curable cancer * Aged ≥18 years * Score in the clinical range (≥22) on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) * Score in the clinical range (\>15) on the Brief Penn State Worry Questionnaire (PSWQ) * Sufficient proficiency in Danish * Able to provide informed consent * Stable or no use of antidepressant or anxiolytic medication (i.e., stable dosage for ≥6 weeks) * Able to participate in online-delivered therapy via a computer with a video camera Exclusion Criteria: * Severe psychiatric conditions (e.g., major depression) that would make participation in the intervention inappropriate * Currently enrolled in psychotherapy or counseling targeting the same problem * Substance abuse or dependence judged to require treatment * Suicide risk requiring immediate psychiatric intervention or hospitalization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fear of cancer progression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancerophobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fear of cancer progression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Psychology and Behavioural Sciences, Aarhus University

    RECRUITING

    Aarhus, 8000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.